R. Sujic
St. Michael's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by R. Sujic.
The Journal of Rheumatology | 2018
Nooshin Khobzi Rotondi; Dorcas E. Beaton; R. Sujic; Joanna Sale; Hina Ansari; Victoria Elliot-Gibson; Earl R. Bogoch; John Cullen; Ravi Jain; Morgan Slater
Objective. To identify and address patient-reported barriers in osteoporosis care after a fracture. Methods. A longitudinal cohort of fragility fracture patients over 50 years of age was seen in a provincewide fracture liaison service. Followup interviews were done at 6 months for osteoporosis care indicators. Univariate statistics were used to describe baseline characteristics, osteoporosis-related outcomes, and reasons cited for not achieving them. Two phases of this program were compared (Phase I: education and communication, and Phase II: risk assessment education and communication). Phase II was further divided into those who fully participated and those who declined. Results. Phase I (n = 3997) had lower testing and treatment rates than Phase II (n = 1363). Rates were highest in those confirmed as having participated in Phase II (n = 569). Phase II nonparticipants (n = 794) had results as in Phase I. In Phase I, the main patient-reported barriers for not visiting their physician or not having a bone mineral density (BMD) test were patient- and physician-oriented (e.g., being instructed by their physician to not have the BMD test). In Phase II, BMD testing was part of the program, thus the main barriers were around treatment choices. Phase II eligible nonparticipants experienced many of the same barriers as Phase I patients, with lower BMD testing rates (54.9% and 65.4%, respectively). Conclusion. Evaluating and addressing barriers to guideline implementation reduced those barriers and was associated with higher downstream treatment rates. Monitoring barriers in a program like this provides useful insights for program changes and research interventions.
Medicine | 2017
Dorcas E. Beaton; Muhammad Mamdani; Hong Zheng; Susan Jaglal; Suzanne M. Cadarette; Earl R. Bogoch; Joanna Sale; R. Sujic; Ravi Jain
Abstract We evaluated a system-wide impact of a health intervention to improve treatment of osteoporosis after a fragility fracture. The intervention consisted of assigning a screening coordinator to selected fracture clinics to identify, educate, and follow up with fragility fracture patients and inform their physicians of the need to evaluate bone health. Thirty-seven hospitals in the province of Ontario (Canada) were assigned a screening coordinator. Twenty-three similar hospitals were control sites. All hospitals had orthopedic services and handled moderate-to-higher volumes of fracture patients. Administrative health data were used to evaluate the impact of the intervention. Fragility fracture patients (≥50 years; hip, humerus, forearm, spine, or pelvis fracture) were identified from administrative health records. Cases were fractures treated at 1 of the 37 hospitals assigned a coordinator. Controls were the same types of fractures at the control sites. Data were assembled for 20 quarters before and 10 quarters after the implementation (from January 2002 to March 2010). To test for a shift in trends, we employed an interrupted time series analysis—a study design used to evaluate the longitudinal effects of interventions, through regression modelling. The primary outcome measure was bone mineral density (BMD) testing. Osteoporosis medication initiation and persistence rates were secondary outcomes in a subset of patients ≥66 years of age. A total of 147,071 patients were used in the analysis. BMD testing rates increased from 17.0% pre-intervention to 20.9% post-intervention at intervention sites (P < .01) compared with no change at control sites (14.9% and 14.9%, P = .33). Medication initiation improved significantly at intervention sites (21.6–23.97%; P = .02) but not at control sites (17.5–18.5%; P = .27). Persistence with bisphosphonates decreased at all sites, from 59.9% to 56.4% at intervention sites (P = .02) and more so from 62.3% to 54.2% at control sites (P < .01) using 50% proportion of days covered (PDC 50). Significant improvements in BMD testing and treatment initiation were observed after the initiation of a coordinator-based screening program to improve osteoporosis management following fragility fracture.
Journal of Evaluation in Clinical Practice | 2010
Joanna Sale; Dorcas E. Beaton; R. Sujic; Earl R. Bogoch
Osteoporosis International | 2014
Dorcas E. Beaton; S. Dyer; D. Jiang; R. Sujic; M. Slater; Joanna Sale; Earl R. Bogoch
Osteoporosis International | 2016
J. H. E. Yong; L. Masucci; Jeffrey S. Hoch; R. Sujic; Dorcas E. Beaton
Maturitas | 2013
R. Sujic; Monique A. M. Gignac; Rhonda Cockerill; Dorcas E. Beaton
Osteoporosis International | 2017
Dorcas E. Beaton; M. Vidmar; K. B. Pitzul; R. Sujic; Nooshin Khobzi Rotondi; Earl R. Bogoch; Joanna E. M. Sale; Rakesh K. Jain; J. Weldon
Osteoporosis International | 2017
H. Ansari; Dorcas E. Beaton; R. Sujic; Nooshin Khobzi Rotondi; J. D. Cullen; M. Slater; Joanna E. M. Sale; Rakesh K. Jain; Earl R. Bogoch
Maturitas | 2016
R. Sujic; Dorcas E. Beaton; Earl R. Bogoch
Bone | 2012
R. Sujic; Dorcas E. Beaton; M. Slater; Earl R. Bogoch